Diabetes Research: Open Access
Hiroshi Bando1,2iD*
1Medical Research/Tokushima University, Tokushima, Japan
2Japan Low Carbohydrate Diet Promotion Association (JLCDPA), Kyoto, Japan
Corresponding Author: Hiroshi Bando ORCID iD
Address: Tokushima University /Medical Research, Nakashowa 1-61, Tokushima 770-0943, Japan.
Received date: 04 February 2024; Accepted date: 02 March 2024; Published date: 09 March 2024
Citation: Bando H. Characteristic points of latest Standards of Medical Care in Diabetes. Diab Res Open Access. 2024 Mar 09;5(1):01-04.
Copyright © 2024 Bando H. This is an open-access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium provided the original work is properly cited.
Keywords: American Diabetes Association, Standards of Medical Care in Diabetes-2024, ADA/EASD Consensus Statement, FreeStyle Libre 2, Appraisal of Guidelines for Research & Evaluation II
Abbreviations: ADA: American Diabetes Association; AGREE II: Appraisal of Guidelines for Research & Evaluation II
Abstract
The American Diabetes Association (ADA) has presented the Standards of Medical Care in Diabetes-2024, introducing some impressive changes in description. The 2024 edition closely follows the ADA/EASD Consensus Statement. To evaluate various complications, BNP, NT-proBNP, ankle-brachial index (ABI), and the FIB-4 index are measured. The administration of SGLT2 inhibitors, GLP-1 receptor agonists, and tirzepatide is recommended for T2D adults with cardiovascular disease, heart failure (including HFrEF/HFpEF), and chronic kidney disease (CKD). For lipid control, bempedoic acid and inclisiran have been introduced. FreeStyle Libre 2 is now available, automatically sending data to the smartphone in real-time every minute.
